Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T
NCT03339661Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Nov 2017
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valganciclovir in cytomegalovirus infection (CMV), sponsored by Centre Hospitalier Universitaire de Bordeaux. Started Nov 2017; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT03339661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03339661.